vs

Side-by-side financial comparison of HERON THERAPEUTICS, INC. (HRTX) and WIDEPOINT CORP (WYY). Click either name above to swap in a different company.

WIDEPOINT CORP is the larger business by last-quarter revenue ($42.3M vs $40.6M, roughly 1.0× HERON THERAPEUTICS, INC.). WIDEPOINT CORP runs the higher net margin — -2.0% vs -7.3%, a 5.3% gap on every dollar of revenue. On growth, WIDEPOINT CORP posted the faster year-over-year revenue change (12.3% vs -0.5%). Over the past eight quarters, WIDEPOINT CORP's revenue compounded faster (11.2% CAGR vs 8.2%).

Antibe Therapeutics was a Toronto-based pharmaceutical company that develops pain and inflammation-reducing drugs based on gaseous mediator technology. Antibe was founded by John L. Wallace, also a co-founder of NicOx, the first company to develop drugs utilizing gaseous mediators. Founded in 2009, the company listed on the TSX Venture Exchange in 2013 and was moved to the Toronto Stock Exchange in November 2020. In 2015, Antibe acquired Citagenix, a distributor involved in regenerative medic...

WidePoint Corporation is an American company based in Fairfax, Virginia that provides technology-based products and services to the government sector and commercial markets in the United States. The company holds a patent for a digital parsing tool that allows users to access accounts through a secure repository gateway, established using asymmetric authentication employed as public key infrastructure (PKI). WidePoint provides smart card identity verification, wireless expense management, pen...

HRTX vs WYY — Head-to-Head

Bigger by revenue
WYY
WYY
1.0× larger
WYY
$42.3M
$40.6M
HRTX
Growing faster (revenue YoY)
WYY
WYY
+12.7% gap
WYY
12.3%
-0.5%
HRTX
Higher net margin
WYY
WYY
5.3% more per $
WYY
-2.0%
-7.3%
HRTX
Faster 2-yr revenue CAGR
WYY
WYY
Annualised
WYY
11.2%
8.2%
HRTX

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
HRTX
HRTX
WYY
WYY
Revenue
$40.6M
$42.3M
Net Profit
$-3.0M
$-849.4K
Gross Margin
72.6%
13.8%
Operating Margin
0.1%
-1.9%
Net Margin
-7.3%
-2.0%
Revenue YoY
-0.5%
12.3%
Net Profit YoY
-180.6%
-138.3%
EPS (diluted)
$-0.01
$-0.08

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
HRTX
HRTX
WYY
WYY
Q4 25
$40.6M
$42.3M
Q3 25
$38.2M
$36.1M
Q2 25
$37.2M
$37.9M
Q1 25
$38.9M
$34.2M
Q4 24
$40.8M
$37.7M
Q3 24
$32.8M
$34.6M
Q2 24
$36.0M
$36.0M
Q1 24
$34.7M
$34.2M
Net Profit
HRTX
HRTX
WYY
WYY
Q4 25
$-3.0M
$-849.4K
Q3 25
$-17.5M
$-559.2K
Q2 25
$-2.4M
$-618.5K
Q1 25
$2.6M
$-724.1K
Q4 24
$3.7M
$-356.4K
Q3 24
$-4.8M
$-425.2K
Q2 24
$-9.2M
$-499.6K
Q1 24
$-3.2M
$-653.1K
Gross Margin
HRTX
HRTX
WYY
WYY
Q4 25
72.6%
13.8%
Q3 25
68.8%
14.6%
Q2 25
73.5%
13.5%
Q1 25
78.3%
14.0%
Q4 24
74.9%
12.6%
Q3 24
71.2%
13.6%
Q2 24
70.8%
13.6%
Q1 24
75.6%
13.6%
Operating Margin
HRTX
HRTX
WYY
WYY
Q4 25
0.1%
-1.9%
Q3 25
-10.7%
-1.3%
Q2 25
-4.4%
-1.9%
Q1 25
8.1%
-2.4%
Q4 24
10.2%
-0.8%
Q3 24
-13.6%
-1.3%
Q2 24
-17.9%
-1.3%
Q1 24
-13.8%
-1.9%
Net Margin
HRTX
HRTX
WYY
WYY
Q4 25
-7.3%
-2.0%
Q3 25
-45.8%
-1.5%
Q2 25
-6.4%
-1.6%
Q1 25
6.8%
-2.1%
Q4 24
9.0%
-0.9%
Q3 24
-14.8%
-1.2%
Q2 24
-25.6%
-1.4%
Q1 24
-9.1%
-1.9%
EPS (diluted)
HRTX
HRTX
WYY
WYY
Q4 25
$-0.01
$-0.08
Q3 25
$-0.10
$-0.06
Q2 25
$-0.02
$-0.06
Q1 25
$0.01
$-0.08
Q4 24
$0.02
$-0.05
Q3 24
$-0.03
$-0.04
Q2 24
$-0.06
$-0.05
Q1 24
$-0.02
$-0.07

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
HRTX
HRTX
WYY
WYY
Cash + ST InvestmentsLiquidity on hand
$28.6M
$9.8M
Total DebtLower is stronger
Stockholders' EquityBook value
$14.3M
$11.5M
Total Assets
$255.9M
$79.8M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
HRTX
HRTX
WYY
WYY
Q4 25
$28.6M
$9.8M
Q3 25
$43.1M
$12.1M
Q2 25
$16.5M
$6.8M
Q1 25
$19.3M
$3.7M
Q4 24
$25.8M
$6.8M
Q3 24
$25.7M
Q2 24
$18.4M
Q1 24
$20.4M
Stockholders' Equity
HRTX
HRTX
WYY
WYY
Q4 25
$14.3M
$11.5M
Q3 25
$14.9M
$12.2M
Q2 25
$-27.3M
$12.6M
Q1 25
$-28.5M
$13.0M
Q4 24
$-33.7M
$13.6M
Q3 24
$-40.0M
$13.8M
Q2 24
$-37.9M
$14.0M
Q1 24
$-33.8M
$14.2M
Total Assets
HRTX
HRTX
WYY
WYY
Q4 25
$255.9M
$79.8M
Q3 25
$248.9M
$70.6M
Q2 25
$232.1M
$76.6M
Q1 25
$235.8M
$71.4M
Q4 24
$233.1M
$71.6M
Q3 24
$220.8M
$56.9M
Q2 24
$218.1M
$58.6M
Q1 24
$217.9M
$54.4M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
HRTX
HRTX
WYY
WYY
Operating Cash FlowLast quarter
$-9.2M
$-173.5K
Free Cash FlowOCF − Capex
$-270.0K
FCF MarginFCF / Revenue
-0.6%
Capex IntensityCapex / Revenue
0.0%
0.2%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$5.5M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
HRTX
HRTX
WYY
WYY
Q4 25
$-9.2M
$-173.5K
Q3 25
$1.3M
$5.9M
Q2 25
$-10.9M
$3.2M
Q1 25
$-8.9M
$-3.2M
Q4 24
$-11.8M
$2.4M
Q3 24
$3.4M
$1.9M
Q2 24
$-4.6M
$-1.1M
Q1 24
$-9.5M
$-1.6M
Free Cash Flow
HRTX
HRTX
WYY
WYY
Q4 25
$-270.0K
Q3 25
$5.9M
Q2 25
$-11.1M
$3.1M
Q1 25
$-9.0M
$-3.3M
Q4 24
$2.4M
Q3 24
$2.9M
$1.8M
Q2 24
$-1.1M
Q1 24
$-1.6M
FCF Margin
HRTX
HRTX
WYY
WYY
Q4 25
-0.6%
Q3 25
16.4%
Q2 25
-29.8%
8.1%
Q1 25
-23.1%
-9.5%
Q4 24
6.4%
Q3 24
9.0%
5.3%
Q2 24
-3.0%
Q1 24
-4.6%
Capex Intensity
HRTX
HRTX
WYY
WYY
Q4 25
0.0%
0.2%
Q3 25
0.0%
0.1%
Q2 25
0.6%
0.2%
Q1 25
0.3%
0.1%
Q4 24
0.1%
Q3 24
1.3%
0.2%
Q2 24
0.0%
Q1 24
0.0%
Cash Conversion
HRTX
HRTX
WYY
WYY
Q4 25
Q3 25
Q2 25
Q1 25
-3.37×
Q4 24
-3.22×
Q3 24
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

HRTX
HRTX

CINVANTI$22.9M56%
ZYNRELEF$12.5M31%
Aponvie$3.8M9%
SUSTOL$1.3M3%

WYY
WYY

Carrier Services$26.8M63%
Managed Services$15.5M37%

Related Comparisons